	US 11,903,947 B2
	Triazine formulations with a second active ingredient and surfactant(s)
Anne-Claire Le Meur, Libourne (FR); and Florence Guimberteau, Montussan (FR)
Assigned to CEVA SANTE ANIMALE, Libourne (FR)
Filed by CEVA SANTE ANIMALE, Libourne (FR)
Filed on May 13, 2022, as Appl. No. 17/743,501.
Application 17/743,501 is a continuation of application No. 14/650,079, granted, now 11,331,321, previously published as PCT/EP2013/075760, filed on Dec. 6, 2013.
Claims priority of application No. 12306548 (EP), filed on Dec. 7, 2012.
Prior Publication US 2022/0265665 A1, Aug. 25, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/53 (2006.01); A61J 1/20 (2006.01); A61K 33/26 (2006.01); A61P 33/02 (2006.01); A61K 9/08 (2006.01); A61K 47/02 (2006.01); A61K 9/10 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/53 (2013.01) [A61J 1/2093 (2013.01); A61K 9/0095 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 33/26 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61P 33/02 (2018.01)]

24 Claims

1. An injectable composition comprising an injectable aqueous suspension, said injectable aqueous suspension comprising:

at least one triazine compound selected from diclazuril and/or toltrazuril;

an iron complex comprising an aqueous colloidal solution of beta-ferric oxyhydroxide and dextran glucoheptonic acid; and

a silicone emulsion, a simethicone emulsion or a combination of a silicone emulsion and a simethicone emulsion, said emulsions having a Hydrophilic-Lipophilic Balance (HLB) of between 1 and 8.